SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Sci Rep · 2018-09-12

DOI: 10.1038/s41598-018-31455-wPMID: 30209317

Open accessPublished Erratum; correctionOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.